142 related articles for article (PubMed ID: 12134948)
1. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE.
Tang F; Borchardt RT
Pharm Res; 2002 Jun; 19(6):787-93. PubMed ID: 12134948
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE.
Tang F; Borchardt RT
Pharm Res; 2002 Jun; 19(6):780-6. PubMed ID: 12134947
[TBL] [Abstract][Full Text] [Related]
3. A modified coumarinic acid-based cyclic prodrug of an opioid peptide: its enzymatic and chemical stability and cell permeation characteristics.
Ouyang H; Tang F; Siahaan TJ; Borchardt RT
Pharm Res; 2002 Jun; 19(6):794-801. PubMed ID: 12134949
[TBL] [Abstract][Full Text] [Related]
4. Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa?
Tang F; Horie K; Borchardt RT
Pharm Res; 2002 Jun; 19(6):773-9. PubMed ID: 12134946
[TBL] [Abstract][Full Text] [Related]
5. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?
Tang F; Horie K; Borchardt RT
Pharm Res; 2002 Jun; 19(6):765-72. PubMed ID: 12134945
[TBL] [Abstract][Full Text] [Related]
6. Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter.
Horie K; Tang F; Borchardt RT
Pharm Res; 2003 Feb; 20(2):161-8. PubMed ID: 12636153
[TBL] [Abstract][Full Text] [Related]
7. Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers.
Bak A; Gudmundsson OS; Friis GJ; Siahaan TJ; Borchardt RT
Pharm Res; 1999 Jan; 16(1):24-9. PubMed ID: 9950274
[TBL] [Abstract][Full Text] [Related]
8. Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-MDR1 cell monolayers.
Tang F; Ouyang H; Yang JZ; Borchardt RT
J Pharm Sci; 2004 May; 93(5):1185-94. PubMed ID: 15067695
[TBL] [Abstract][Full Text] [Related]
9. Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability.
Gudmundsson OS; Pauletti GM; Wang W; Shan D; Zhang H; Wang B; Borchardt RT
Pharm Res; 1999 Jan; 16(1):7-15. PubMed ID: 9950272
[TBL] [Abstract][Full Text] [Related]
10. Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeation.
Gudmundsson OS; Nimkar K; Gangwar S; Siahaan T; Borchardt RT
Pharm Res; 1999 Jan; 16(1):16-23. PubMed ID: 9950273
[TBL] [Abstract][Full Text] [Related]
11. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers.
Zhang Y; Benet LZ
Pharm Res; 1998 Oct; 15(10):1520-4. PubMed ID: 9794492
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and conformational analysis of a coumarinic acid-based cyclic prodrug of an opioid peptide with modified sensitivity to esterase-catalyzed bioconversion.
Ouyang H; Vander Velde DG; Borchardt RT; Siahaan TJ
J Pept Res; 2002 Apr; 59(4):183-95. PubMed ID: 11972752
[TBL] [Abstract][Full Text] [Related]
13. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
Guo A; Marinaro W; Hu P; Sinko PJ
Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
[TBL] [Abstract][Full Text] [Related]
14. Transport characteristics of peptidomimetics. Effect of the pyrrolinone bioisostere on transport across Caco-2 cell monolayers.
Sudoh M; Pauletti GM; Yao W; Moser W; Yokoyama A; Pasternak A; Sprengeler PA; Smith AB; Hirschmann R; Borchardt RT
Pharm Res; 1998 May; 15(5):719-25. PubMed ID: 9619780
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model.
Karyekar CS; Eddington ND; Garimella TS; Gubbins PO; Dowling TC
Pharmacotherapy; 2003 Apr; 23(4):436-42. PubMed ID: 12680473
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using coumarinic acid and phenylpropionic acid linkers.
Wang B; Nimkar K; Wang W; Zhang H; Shan D; Gudmundsson O; Gangwar S; Siahaan T; Borchardt RT
J Pept Res; 1999 Apr; 53(4):370-82. PubMed ID: 10406215
[TBL] [Abstract][Full Text] [Related]
17. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.
Luo FR; Paranjpe PV; Guo A; Rubin E; Sinko P
Drug Metab Dispos; 2002 Jul; 30(7):763-70. PubMed ID: 12065434
[TBL] [Abstract][Full Text] [Related]
18. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
19. Optimizing oral absorption of peptides using prodrug strategies.
Borchardt RT
J Control Release; 1999 Nov; 62(1-2):231-8. PubMed ID: 10518655
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport.
Augustijns PF; Bradshaw TP; Gan LS; Hendren RW; Thakker DR
Biochem Biophys Res Commun; 1993 Dec; 197(2):360-5. PubMed ID: 7903526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]